Discussions With FDA Provide Guidance for Phase IIb Clinical Trial Design for DMT-Assisted Therapy for Major Depressive Disorder
FDA discussions pave pathway for U.S. clinical trial preparations LONDON, Nov. 15, 2021 (GLOBE NEWSWIRE) — Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a neuropharmaceutical company focused on psychedelic-assisted therapies today confirms, following positive discussions with the U.S. Food and Drug Administration (the “FDA”), that preparations are now underway for […]
atai Life Sciences Reports Third Quarter 2021 Financial Results and Corporate Update
-Positive topline results from COMP360’s Phase 2b study- -RL-007 Phase 2a topline data in cognitive impairment associated with schizophrenia expected end of Q4- -Continued progress across 11 therapeutic programs, including initiation of Perception’s Phase 2a and DemeRx’s Phase 1/2 trials as well as interim Phase 2a RL-007 readout of first cohort- -Launch of atai Impact, a […]
Cybin Inc. Reports its Second Quarter Financial Results and Recent Business Highlights
Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to TherapeuticsTM”, today reported unaudited financial results for its second quarter ended September 30, 2021. “The first half of the year has been a transformative period for Cybin that included significant and swift advancements in our research and development pipeline […]
